Global Liposomal Drugs Market, By Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphoteracin B, Others), Application (Fungal Infection Therapy, Cancer and Tumor Therapy, Ocular and Pulmonary), Industry (Pharmaceutical, Cosmetic, Food, Farming) – Industry Trends and Forecast to 2029
Liposomal Drugs Market Analysis and Size
The global liposomal drugs market is expected to witness significant growth during the forecast period. Liposomes help in delivering drugs by the process of diffusion rather than by direct cell fusion. They enable a diverse range of drugs that is encapsulated by these vesicles, which contributes to the growth of the global market. The increasing incidence of fungal disorders is prompting a lot in increasing the demand for liposomal formulations of Amphotericin B. Thus, it helps in leading the market growth.
Data Bridge Market Research analyses a growth rate in the global liposomal drugs market in the forecast period 2022-2029. The expected CAGR of global liposomal drugs market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 4.16 billion in 2021, and it would grow upto USD 7.99 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Liposome can be defined as a spherical-shaped vesicle that involves one or more phospholipid bilayers, similar to the structure of cell membranes. The liposome focusses on a particular part or tissue instead of whole body part. Liposome operates as a tool and reproduction in many scientific fields. This is further anticipated to impede the growth of the liposomal drugs market in the timeline period.
Liposomal Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphoteracin B, Others), Application (Fungal Infection Therapy, Cancer and Tumor Therapy, Ocular and Pulmonary), Industry (Pharmaceutical, Cosmetic, Food, Farming)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Serum Institute of India Pvt. Ltd. (India), Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd (China), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Janssen Global Services, LLC (Belgium), CELSION corporation (U.S.), Abbott (U.S.), Ipsen Pharma (France), Spectrum Pharmaceuticals, Inc. (U.S.), Takeda Pharmaceutical Company Limited. (Japan), Merrimack (U.S.), Evonik Industries AG (Germany)
|
|
Market Opportunities
|
|
Global Liposomal Drugs Market Dynamics
Drivers
- Greater Adoption of Quality by Design (QbD) Over Traditional Processes
Processes have been streamlined as a result of the adoption of rational-based approaches such as QbD over empirical and simulation-based approaches. In comparison to conventional methodologies focused on trial and error, QbD is based on a fact-based rational approach and aids in more robust decision-making. The popularity and implementation of the QbD technique are anticipated to rise.
- Increasing Use of Liposomal contrast imaging agents
Liposomes are conditioned for therapeutic, diagnostic, and image-guided drug delivery. Paramagnetic liposomes are widely used in molecular and cell imaging and image-guided drug delivery.
Drug-loaded paramagnetic liposomes have been used for therapeutic interventions. Liposomes have long been provided as a medium for delivering paramagnetic ions. Increasing imaging modalities such as MRI, CT scans and SPECT imaging are expected to complement the growth of the global liposome market.
Opportunities
- Enhancing Circulation Time of Hydrophobic Substances
Galbanic acid (Gba) in improved liposomal formulations is being used in the liposome drug delivery market to maximise the therapeutic efficacy of PEGylated liposomal Doxorubicin. A sesquiterpene coumarin with powerful antiangiogenic properties, galvanic acid has a promising future as an anti-cancer drug. Galbanic acid's water solubility restrictions limit its potential for use in medicine. To get around the drawbacks of poor Gba solubility, businesses in the liposome drug delivery market are expanding the application of PEGylated liposomal Gba made using the thin film hydration plus extrusion approach.
- Advanced Clinical Research and Technological Advancement
For pharmaceutical businesses, new methods for liposome surface modification are creating more opportunities. As a valuable biocompatible instrument for the vehiculation and administration of lipophilic, hydrophilic, and ampiphilic chemicals, liposome drug delivery is receiving a lot of attention. However, some of the challenges faced by businesses in the liposome drug delivery market include significant toxicity and resistance in large dosages. As a result, businesses are converting from basic conventional vesicles to second-generation liposomes by adjusting the surface and lipid composition with various ligands.
Restraints/Challenges
- High Cost
The huge expenditure required for developing the liposomal drugs surely hamper the market growth.
This global liposomal drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global liposomal drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Liposomal Drugs Market Scope
The global liposomal drugs market is segmented on the basis of type, application, industry. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Liposomal Doxorubicin
- Liposomal Paclitaxel
- Liposomal Amphoteracin B
- Others
Application
- Fungal Infection Therapy
- Cancer and Tumor Therapy
- Ocular and Pulmonary
Industry
- Pharmaceutical
- Cosmetic
- Food
- Farming
Liposomal Drugs Market Regional Analysis/Insights
The global liposomal drugs market is analysed and market size insights and trends are provided by type, application, industry as referenced above.
The major countries covered in the global liposomal drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the liposomal drugs market due to the occurrence of major key players. Furthermore, the rise in the incidences of cancer will further boost the growth of the liposomal drugs market in the region during the forecast period. Asia-Pacific is projected to observe significant growth in the liposomal drugs market due to the rise in the number of patients suffering from chronic diseases. Moreover, the players' attention on bolstering the existence in the advancing countries is further anticipated to propel the growth of the liposomal drugs market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Liposomal Drugs Market Share Analysis
The global liposomal drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global liposomal drugs market
Key players operating in the global liposomal drugs market include:
- Johnson & Johnson Services, Inc. (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Serum Institute of India Pvt. Ltd. (India)
- Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd (China)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Janssen Pharmaceuticals, Inc. (Belgium)
- CELSION corporation (U.S.)
- Abbott (U.S.)
- Ipsen Pharma (France)
- Spectrum Pharmaceuticals, Inc. (U.S.)
- Takeda Pharmaceutical Company Limited. (Japan)
- Merrimack Pharmaceuticals (U.S.)
- Evonik Industries AG (Germany)
SKU-